Severe COVID-19-related Pneumonia Seven Years after Heart Transplantation

A 67-year-old man on intense immunosuppressive therapy after heart transplantation for end-stage hypertrophic cardiomyopathy 7 years ago developed severe dyspnea and was admitted to our hospital. His serum severe acute respiratory syndrome coronavirus 2 antigen test was positive, and he was diagnosed with coronavirus disease 2019 (COVID-19)-related pneumonia. He was started on ventilatory management for severe respiratory failure and remdesivir for COVID-19, with careful adjustment of immunosuppressive drugs. However, unexpectedly prolonged muscle weakness necessitated transfer to a rehabilitation facility. Although the COVID-19 pandemic has subsided, it is still considered a risk in post-transplant cases. Infection control is considered critical in heart transplant recipients, especially in those receiving intensified immunosuppressive drugs.

Authors

Institutions

Publication Details

Journal
Internal Medicine
Published
2025-04-04
DOI
https://doi.org/10.2169/internalmedicine.5254-25
Citations
1
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
1.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Severe COVID-19-related Pneumonia Seven Years after Heart Transplantation

Gentaro Taniguchi, Shunsuke Katsuki, Akira Shiose, Kayo Misumi et al.
1 citations
Internal Medicine
COVID-19 Clinical Research Studies
1.40
article

Severe COVID-19-related Pneumonia Seven Years after Heart Transplantation

Gentaro Taniguchi, Shunsuke Katsuki, Akira Shiose, Kayo Misumi, Keisuke Shinohara, Shouji Matsushima, Hiroshi Kisanuki, Kohtaro Abe, Takeo Fujino, Toru Hashimoto
article en
1 citations

Abstract

A 67-year-old man on intense immunosuppressive therapy after heart transplantation for end-stage hypertrophic cardiomyopathy 7 years ago developed severe dyspnea and was admitted to our hospital. His serum severe acute respiratory syndrome coronavirus 2 antigen test was positive, and he was diagnosed with coronavirus disease 2019 (COVID-19)-related pneumonia. He was started on ventilatory management for severe respiratory failure and remdesivir for COVID-19, with careful adjustment of immunosuppressive drugs. However, unexpectedly prolonged muscle weakness necessitated transfer to a rehabilitation facility. Although the COVID-19 pandemic has subsided, it is still considered a risk in post-transplant cases. Infection control is considered critical in heart transplant recipients, especially in those receiving intensified immunosuppressive drugs.

Internal MedicineVol. 64(12)
Kyushu University (JP)
Good health and well-being
Openalex Percentile: Top 22%
COVID-19 Clinical Research Studies
1.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.